Lifecore biomedical reports second quarter fiscal year 2023 results

Company announces intention to explore strategic alternatives signs term sheet with key customer to materially expand commercial relationship expands development pipeline from 24 to 25 active projects as of fiscal second quarter-end subsequently transitioned three projects to commercialization with fda approval in fiscal third quarter, expanding commercial products from 26 to 29 with 14 customers fiscal second quarter earnings call scheduled for march 17th, 2023 at 8:30 am eastern time
LFCR Ratings Summary
LFCR Quant Ranking